A neurological syndrome characterized by clumsy and uncoordinated movement of the limbs, trunk, and cranial muscles. It results from pathology in the cerebellum and its connections, or in the proprioc...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding cerebellar ataxia is limited due to the condition's rarity, which affects fewer than 200,000 people in the United States. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. Additionally, the complex nature of ataxia can overlap with other neurological disorders, making it challenging to delineate specific clinical features.
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Currently, there are several orphan drugs in development for cerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and others. There are also 135 active clinical trials aimed at exploring various aspects of the condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=cerebellar%20ataxia.
Actionable guidance for navigating care for cerebellar ataxia
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cerebellar ataxia is limited due to the condition's rarity, which affects fewer than 200,000 people in the United States. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. Additionally, the complex nature of ataxia can overlap with other neurological disorders, making it challenging to delineate specific clinical features.
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Currently, there are several orphan drugs in development for cerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and others. There are also 135 active clinical trials aimed at exploring various aspects of the condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=cerebellar%20ataxia.
Actionable guidance for navigating care for cerebellar ataxia
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cerebellar ataxia is limited due to the condition's rarity, which affects fewer than 200,000 people in the United States. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. Additionally, the complex nature of ataxia can overlap with other neurological disorders, making it challenging to delineate specific clinical features.
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Currently, there are several orphan drugs in development for cerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and others. There are also 135 active clinical trials aimed at exploring various aspects of the condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=cerebellar%20ataxia.
Actionable guidance for navigating care for cerebellar ataxia
To navigate your care for cerebellar ataxia, consider seeking a neurologist with expertise in hereditary ataxias, as they will have the specialized knowledge to guide your treatment options. Additionally, while no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Participating in clinical trials may also be an option; explore the active studies listed on ClinicalTrials.gov for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.